Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd has achieved a milestone in its U.S. commercial rollout of Remplir™, with 100 units sold in the $1.6 billion U.S. nerve repair market. This accomplishment reflects growing adoption fueled by a robust medical education campaign and a specialized distributor network. The company’s early success, including significant hospital VAC approvals, positions Remplir™ for future growth in both the U.S. and Canada, targeting a combined addressable market of $3.5 billion. Leveraging strong distribution frameworks and a debt-free financial position, Orthocell aims to accelerate its global market expansion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company specializing in innovative solutions for nerve repair and tissue regeneration. Its flagship product, Remplir™, targets the peripheral nerve repair market and aims to enhance patient outcomes in this specialized area.
Average Trading Volume: 813,607
Technical Sentiment Signal: Buy
Current Market Cap: A$276.5M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.